NCT04852588 Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment
| NCT ID | NCT04852588 |
| Status | Recruiting |
| Phase | — |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Condition | Non-Small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 29 participants |
| Start Date | 2021-11-09 |
| Primary Completion | 2025-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 29 participants in total. It began in 2021-11-09 with a primary completion date of 2025-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will investigate the role of sampling suspicious chest lymph nodes with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA) in patients planned to receive radical dose radiation. This study will use Stereotactic Ablative Radiotherapy (SABR) for treatment methods. SABR is a newer radiation treatment that delivers high-dose, precise radiation to small tumors and can be delivered more accurately than with older radiation treatment methods. It is considered a standard treatment for small lung cancers, and select cancers that have spread to the brain. The purpose of this study is to compare if the lymph node sampling procedure is valuable for determining the extend of nodal disease in metastatic Non-Small Cell Lung Cancer (NSCLC) compared to imaging alone.
Eligibility Criteria
Inclusion Criteria: * Patients with oligometastatic non-small cell lung cancer (NSCLC), including a primary lung tumour (± hilar/mediastinal adenopathy) with up to 5 synchronous metastases * Radical treatment intent to all sites is recommended at multi-disciplinary tumour board or by discussion by medical oncologist and radiation oncologist and/or surgeon. * Age 18 years or older * Good performance status (Eastern Cooperative Oncology Group \[ECOG 0-1) with life-expectancy of at least 6 months as determined by enrolling physician * Patient has undergone staging investigations less than 3 months prior to registration. 1. Positron Emission Tomography (PET) / Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) brain (CT brain with contrast if contraindication to MRI) OR 2. CT chest/abdomen, radionucleotide bone scan and MRI of brain (CT brain with contrast if contraindication to MRI) * Pathologic confirmation of NSCLC Exclusion Criteria: * Contraindication to Endobronchial Ultrasound (EBUS) / Endoscopic Ultrasound (EUS) * Unable to provide consent for EBUS/EUS * Contraindication to chest radiotherapy * Pregnant or lactating women
Contact & Investigator
Inderdeep Dhaliwal, MD
PRINCIPAL INVESTIGATOR
London Health Sciences Centre, Lawson Health Research Institute
Frequently Asked Questions
Who can join the NCT04852588 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04852588 currently recruiting?
Yes, NCT04852588 is actively recruiting participants. Contact the research team at Inderdeep.Dhaliwal@lhsc.on.ca for enrollment information.
Where is the NCT04852588 trial being conducted?
This trial is being conducted at London, Canada, Toronto, Canada.
Who is sponsoring the NCT04852588 clinical trial?
NCT04852588 is sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. The principal investigator is Inderdeep Dhaliwal, MD at London Health Sciences Centre, Lawson Health Research Institute. The trial plans to enroll 29 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.